Merck Lands Late-Stage Enbrel Biosimilar In Deal With South Korea's Hanwha
This article was originally published in The Pink Sheet Daily
Executive Summary
The addition of the Phase III candidate to its portfolio positions Merck as a leader in the race to launch a low-cost version of a major rheumatoid arthritis drug.